Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 89

1.

Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction.

Bornschein J, Wernisch L, Secrier M, Miremadi A, Perner J, MacRae S, O'Donovan M, Newton R, Menon S, Bower L, Eldridge MD, Devonshire G, Cheah C, Turkington R, Hardwick RH, Selgrad M, Venerito M, Malfertheiner P; OCCAMS Consortium, Fitzgerald RC.

Int J Cancer. 2019 May 3. doi: 10.1002/ijc.32384. [Epub ahead of print]

PMID:
31050820
2.

Regulation of the Expression of DAPK1 by SUMO Pathway.

Wang Q, Zhang X, Chen L, Weng S, Xia Y, Ye Y, Li K, Liao Z, Chen P, Alsamman K, Meng C, Stevens C, Hupp TR, Lin Y.

Biomolecules. 2019 Apr 17;9(4). pii: E151. doi: 10.3390/biom9040151.

3.

The effects of IFITM1 and IFITM3 gene deletion on IFNγ stimulated protein synthesis.

Gómez-Herranz M, Nekulova M, Faktor J, Hernychova L, Kote S, Sinclair EH, Nenutil R, Vojtesek B, Ball KL, Hupp TR.

Cell Signal. 2019 Aug;60:39-56. doi: 10.1016/j.cellsig.2019.03.024. Epub 2019 Apr 2.

PMID:
30951861
4.

An inter-subunit protein-peptide interface that stabilizes the specific activity and oligomerization of the AAA+ chaperone Reptin.

Coufalova D, Remnant L, Hernychova L, Muller P, Healy A, Kannan S, Westwood N, Verma CS, Vojtesek B, Hupp TR, Houston DR.

J Proteomics. 2019 May 15;199:89-101. doi: 10.1016/j.jprot.2019.02.012. Epub 2019 Mar 9.

PMID:
30862565
5.

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.

Turkington RC, Knight LA, Blayney JK, Secrier M, Douglas R, Parkes EE, Sutton EK, Stevenson L, McManus D, Halliday S, McCavigan AM, Logan GE, Walker SM, Steele CJ, Perner J, Bornschein J, MacRae S, Miremadi A, McCarron E, McQuaid S, Arthur K, James JA, Eatock MM, O'Neill R, Noble F, Underwood TJ, Harkin DP, Salto-Tellez M, Fitzgerald RC, Kennedy RD; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group.

Gut. 2019 Mar 9. pii: gutjnl-2018-317624. doi: 10.1136/gutjnl-2018-317624. [Epub ahead of print]

6.

The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic.

Frankell AM, Jammula S, Li X, Contino G, Killcoyne S, Abbas S, Perner J, Bower L, Devonshire G, Ococks E, Grehan N, Mok J, O'Donovan M, MacRae S, Eldridge MD, Tavaré S; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Fitzgerald RC.

Nat Genet. 2019 Mar;51(3):506-516. doi: 10.1038/s41588-018-0331-5. Epub 2019 Feb 4.

PMID:
30718927
7.

Author Correction: Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1.

Garcia E, Hayden A, Birts C, Britton E, Rogerson C, Bleaney CW, Cowie A, Pickard K, Mellone M, Choh C, Derouet M, Duriez P, Noble F, White MJ, Primrose JN, Strefford JC, Rose-Zerilli M, Thomas GJ, Ang Y, Sharrocks AD, Fitzgerald RC, Underwood TJ; OCCAMS consortium.

Sci Rep. 2019 Jan 22;9(1):318. doi: 10.1038/s41598-018-37591-7.

8.

Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts.

Sawas T, Killcoyne S, Iyer PG, Wang KK, Smyrk TC, Kisiel JB, Qin Y, Ahlquist DA, Rustgi AK, Costa RJ, Gerstung M, Fitzgerald RC, Katzka DA; OCCAMS Consortium.

Gastroenterology. 2018 Dec;155(6):1720-1728.e4. doi: 10.1053/j.gastro.2018.08.036. Epub 2018 Aug 27.

9.

The Sequence-specific Peptide-binding Activity of the Protein Sulfide Isomerase AGR2 Directs Its Stable Binding to the Oncogenic Receptor EpCAM.

Mohtar MA, Hernychova L, O'Neill JR, Lawrence ML, Murray E, Vojtesek B, Hupp TR.

Mol Cell Proteomics. 2018 Apr;17(4):737-763. doi: 10.1074/mcp.RA118.000573. Epub 2018 Jan 16.

10.

Mono-Substituted Hydrocarbon Diastereomer Combinations Reveal Stapled Peptides with High Structural Fidelity.

McWhinnie FS, Sepp K, Wilson C, Kunath T, Hupp TR, Baker TS, Houston DR, Hulme AN.

Chemistry. 2018 Feb 9;24(9):2094-2097. doi: 10.1002/chem.201705983. Epub 2018 Jan 19.

PMID:
29267987
11.

A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy.

Noorani A, Bornschein J, Lynch AG, Secrier M, Achilleos A, Eldridge M, Bower L, Weaver JMJ, Crawte J, Ong CA, Shannon N, MacRae S, Grehan N, Nutzinger B, O'Donovan M, Hardwick R, Tavaré S, Fitzgerald RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium.

Genome Res. 2017 Jun;27(6):902-912. doi: 10.1101/gr.214296.116. Epub 2017 May 2. Erratum in: Genome Res. 2017 Oct;27(10 ):1782.

12.

Regulation of transcriptional activators by DNA-binding domain ubiquitination.

Landré V, Revi B, Mir MG, Verma C, Hupp TR, Gilbert N, Ball KL.

Cell Death Differ. 2017 May;24(5):903-916. doi: 10.1038/cdd.2017.42. Epub 2017 Mar 31.

13.

Quantitative Shotgun Proteomics Unveils Candidate Novel Esophageal Adenocarcinoma (EAC)-specific Proteins.

O'Neill JR, Pak HS, Pairo-Castineira E, Save V, Paterson-Brown S, Nenutil R, Vojtěšek B, Overton I, Scherl A, Hupp TR.

Mol Cell Proteomics. 2017 Jun;16(6):1138-1150. doi: 10.1074/mcp.M116.065078. Epub 2017 Mar 23.

14.

Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1.

Garcia E, Hayden A, Birts C, Britton E, Cowie A, Pickard K, Mellone M, Choh C, Derouet M, Duriez P, Noble F, White MJ, Primrose JN, Strefford JC, Rose-Zerilli M, Thomas GJ, Ang Y, Sharrocks AD, Fitzgerald RC, Underwood TJ; OCCAMS consortium.

Sci Rep. 2016 Sep 7;6:32417. doi: 10.1038/srep32417. Erratum in: Sci Rep. 2019 Jan 22;9(1):318.

15.

Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.

Secrier M, Li X, de Silva N, Eldridge MD, Contino G, Bornschein J, MacRae S, Grehan N, O'Donovan M, Miremadi A, Yang TP, Bower L, Chettouh H, Crawte J, Galeano-Dalmau N, Grabowska A, Saunders J, Underwood T, Waddell N, Barbour AP, Nutzinger B, Achilleos A, Edwards PA, Lynch AG, Tavaré S, Fitzgerald RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium.

Nat Genet. 2016 Oct;48(10):1131-41. doi: 10.1038/ng.3659. Epub 2016 Sep 5. Erratum in: Nat Genet. 2017 Jan 31;49(2):317.

16.

The Development of a Recombinant scFv Monoclonal Antibody Targeting Canine CD20 for Use in Comparative Medicine.

Jain S, Aresu L, Comazzi S, Shi J, Worrall E, Clayton J, Humphries W, Hemmington S, Davis P, Murray E, Limeneh AA, Ball K, Ruckova E, Muller P, Vojtesek B, Fahraeus R, Argyle D, Hupp TR.

PLoS One. 2016 Feb 19;11(2):e0148366. doi: 10.1371/journal.pone.0148366. eCollection 2016.

17.

Mass spectrometry analysis of the oxidation states of the pro-oncogenic protein anterior gradient-2 reveals covalent dimerization via an intermolecular disulphide bond.

Clarke DJ, Murray E, Faktor J, Mohtar A, Vojtesek B, MacKay CL, Smith PL, Hupp TR.

Biochim Biophys Acta. 2016 May;1864(5):551-61. doi: 10.1016/j.bbapap.2016.02.011. Epub 2016 Feb 10.

18.

Hammock: a hidden Markov model-based peptide clustering algorithm to identify protein-interaction consensus motifs in large datasets.

Krejci A, Hupp TR, Lexa M, Vojtesek B, Muller P.

Bioinformatics. 2016 Jan 1;32(1):9-16. doi: 10.1093/bioinformatics/btv522. Epub 2015 Sep 5.

19.

The use of ion mobility mass spectrometry to probe modulation of the structure of p53 and of MDM2 by small molecule inhibitors.

Dickinson ER, Jurneczko E, Nicholson J, Hupp TR, Zawacka-Pankau J, Selivanova G, Barran PE.

Front Mol Biosci. 2015 Jul 10;2:39. doi: 10.3389/fmolb.2015.00039. eCollection 2015.

20.

MAGE-A Cancer/Testis Antigens Inhibit MDM2 Ubiquitylation Function and Promote Increased Levels of MDM4.

Marcar L, Ihrig B, Hourihan J, Bray SE, Quinlan PR, Jordan LB, Thompson AM, Hupp TR, Meek DW.

PLoS One. 2015 May 22;10(5):e0127713. doi: 10.1371/journal.pone.0127713. eCollection 2015.

Supplemental Content

Loading ...
Support Center